Compare Amazon.com Inc (AMZN) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amazon.com Inc vs Sana Biotechnology Inc — how do they compare? Amazon.com Inc trades at $267.74 (market cap $2.94T), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Amazon.com Inc is far larger — about 2601.8× Sana Biotechnology Inc's market cap, and Amazon.com Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| AMZN | SANA | |
|---|---|---|
Market Cap | $2.94T | $1.13B |
Volume | 3,931,282 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $284.02 | $5.92 |
52-Week Low | $198.79 | $2.68 |
Enterprise Value | $3.04T | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amazon (AMZN) trades at $272.27, down 2.09% today but maintains strong fundamentals with robust revenue growth from $638B in 2024 to $716.9B in 2025 and net income surging to $77.67B. Technical indicators show a bullish trend with support at $271 and resistance at $275, while analyst consensus remains overwhelmingly positive with 89% buy ratings and a $333.86 price target. Recent news highlights CEO Andy Jassy's optimistic outlook on AWS growth and AI chip business expansion.
Amazon presents a compelling investment case with accelerating profitability and dominant market positioning, though investors face risks from intense competition and significant capital expenditures. The stock's current valuation at 21.9x P/E appears reasonable given projected 2026 net income growth to $135.3B, supporting potential upside to analyst targets despite near-term market volatility.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amazon.com Inc
Amazon.com, Inc. is an online retailer that offers a wide range of products. The Company products include books, music, computers, electronics and numerous other products. Amazon offers personalized shopping services, Web-based credit card payment, and direct shipping to customers. Amazon also operates a cloud platform offering services globally.
Read more on AMZN →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
